Gounder, M., Schöffski, P., Jones, R. L., Agulnik, M., Cote, G. M., Villalobos, V. M., Attia, S., Chugh, R., Chen, T. W., Jahan, T., Loggers, E. T., Gupta, A., Italiano, A., Demetri, G. D., Ratan, R., Davis, L. E., Mir, O., Dileo, P., Van Tine, B. A., Pressey, J. G., Lingaraj, T., Rajarethinam, A., Sierra, L., Agarwal, S., & Stacchiotti, S. (2020). Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study. Lancet Oncol, 21(11), 1423-1432. https://doi.org/10.1016/s1470-2045(20)30451-4

Gounder, M., Schöffski, P., Jones, R. L., Agulnik, M., Cote, G. M., Villalobos, V. M., Attia, S., Chugh, R., Chen, T. W., Jahan, T., Loggers, E. T., Gupta, A., Italiano, A., Demetri, G. D., Ratan, R., Davis, L. E., Mir, O., Dileo, P., Van Tine, B. A., Pressey, J. G., Lingaraj, T., Rajarethinam, A., Sierra, L., Agarwal, S., & Stacchiotti, S. (2020). Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study. Lancet Oncol, 21(11), 1423-1432. https://doi.org/10.1016/s1470-2045(20)30451-4